BC
NVO

Brookfield Corp’s Novo Nordisk NVO Stock Holding History

Brookfield Corp’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-269,808
Closed -$18.3M – 745
2022
Q4 		$18.3M Buy
+269,808
New +$15.8M 0.07% 99
2022
Q3 		– Sell
-241,036
Closed -$13.4M – 732
2022
Q2 		$13.4M Sell
241,036
-115,256
-32% -$6.4M 0.06% 114
2022
Q1 		$19.8M Buy
+356,292
New +$18.3M 0.07% 96
2021
Q4 		– Sell
-117,278
Closed -$5.63M – 709
2021
Q3 		$5.63M Buy
117,278
+69,542
+146% +$3.36M 0.02% 202
2021
Q2 		$2M Sell
47,736
-42,024
-47% -$1.63M 0.01% 355
2021
Q1 		$3.03M Buy
+89,760
New +$3.2M 0.01% 230

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Brookfield Corp's NVO Position: Q1 2023 in Review

Brookfield Corp sold out of Novo Nordisk (NVO) in Q1 2023, closing a stake of 269,808 shares — an estimated $18.3M sold.

Brookfield Corp first reported a position in NVO in Q1 2021 and held it in 6 quarters. The position peaked at $19.8M in Q1 2022. 1,145 funds tracked by Wall St. Rank hold NVO as of Q1 2023.

  • Brookfield Corp reported no remaining Novo Nordisk position as of Q1 2023 after selling out during the quarter.
  • Brookfield Corp sold 269,808 Novo Nordisk shares in Q1 2023, an estimated $18.3M.
  • Brookfield Corp first reported a position in Novo Nordisk in Q1 2021 and held it in 6 quarters.
  • Brookfield Corp's Novo Nordisk position peaked at $19.8M in Q1 2022.
  • 1,145 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.